ALPINE IMMUNE SCIENCES, INC. Quarterly Debt-to-equity in % from Q2 2018 to Q1 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Alpine Immune Sciences, Inc. quarterly Debt-to-equity history and growth rate from Q2 2018 to Q1 2024.
  • Alpine Immune Sciences, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 25.7 %, a 61.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 25.7 -41.8 -61.9% Mar 31, 2024
Q4 2023 37 -41.3 -52.7% Dec 31, 2023
Q3 2023 53.3 -39.3 -42.5% Sep 30, 2023
Q2 2023 56.1 -48.7 -46.4% Jun 30, 2023
Q1 2023 67.5 -51.6 -43.3% Mar 31, 2023
Q4 2022 78.4 -50.2 -39.1% Dec 31, 2022
Q3 2022 92.6 -44 -32.2% Sep 30, 2022
Q2 2022 105 -54.5 -34.2% Jun 30, 2022
Q1 2022 119 -47.4 -28.5% Mar 31, 2022
Q4 2021 129 -35.4 -21.6% Dec 31, 2021
Q3 2021 137 -24.7 -15.3% Sep 30, 2021
Q2 2021 159 +1.79 +1.14% Jun 30, 2021
Q1 2021 167 +89.1 +115% Mar 31, 2021
Q4 2020 164 +110 +204% Dec 31, 2020
Q3 2020 161 +120 +288% Sep 30, 2020
Q2 2020 157 +130 +477% Jun 30, 2020
Q1 2020 77.4 +60.8 +367% Mar 31, 2020
Q4 2019 53.9 +40.1 +290% Dec 31, 2019
Q3 2019 41.6 +30.9 +290% Sep 30, 2019
Q2 2019 27.3 +18.2 +200% Jun 30, 2019
Q1 2019 16.6 Mar 31, 2019
Q4 2018 13.8 Dec 31, 2018
Q3 2018 10.7 Sep 30, 2018
Q2 2018 9.1 Jun 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.